Molecular and Cellular Oncology
Versiti Diagnostic Labs provide innovative diagnostic and prognostic testing in blood cancers to support patient stratification, therapeutic decision and targeted therapy for cancer. We deliver novel testing services that provide critical clinical direction in complex cases of acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and chronic myelogenous leukemia (CML).
The Value of Molecular Oncology Testing from Versiti
- Don’t wait for precision laboratory medicine. Since the launch of both IDH assays in August 2018, Versiti has rapidly reported test results within an average of four days.
- Identify more patients who could benefit from new targeted therapies. IDH Abbott tests have high detection rates, down to 1% mutational burden as documented in FDA submissions.
- The LeukoStrat FLT3 test is the only internationally standardized quantitative test for both ITD and TKD mutations.
Companion Diagnostic Tests
LeukoStrat CDx FLT3 Mutation Assay (Test Code: 4675
LeukoStrat CDx FLT3 aids in identifying acute myeloid leukemia (AML) patients with an FLT3 mutation for treatment with FDA-approved drugs RYDAPT® (midostaurin) and XOSPATA® (gilteritinib).
IDH1 Abbott Realtime PCR Test (Test Code: 7647)
IDH1 Abbott Realtime PCR aids in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib).
IDH2 Abbott Realtime PCR Test (Test Code: 7648)
IDH2 Abbott Realtime PCR aids in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA® (enasidenib).
Precision Medicine Expertise
Sign Up for Versiti Updates
Sign up for our newsletter to be notified of upcoming conferences we will be attending, new tests, and much more.